ClinicalTrials.gg
CompletedNCT04223791Updated Mar 27, 2026Results posted

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 89 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
643
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Enrollment
6th of 66
643 · median 163
Started
2020
with 2 others
Phase 3
21 of 75
none open now
Registered
71st of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 6th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 in phase 3, and was the 71st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency virus-1 (HIV-1) virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to DOR/ISL (MK-8591A) will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive with plasma Human Immunodeficiency Virus 1 (HIV-1) RNA \<50 copies/mL at screening.
  • Has been receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy with documented viral suppression (HIV-1 RNA \<50 copies/mL) for ≥3 months prior to signing and has no history of prior virologic treatment failure on any past or current regimen.
  • Females are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of (WOCBP); is a WOCBP and using an acceptable method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention; if a urine test cannot be confirmed as negative (e.g. an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection.
  • Has an active diagnosis of hepatitis due to any cause, including active Virus (HBV) co-infection.
  • Has a history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma.
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies.
  • Is currently participating in or has participated in a clinical study with an compound or device from 45 days prior to Day 1 through the study treatment period.
  • Has a documented or known virologic resistance to doravirine (DOR).
  • expects to conceive or donate eggs at any time during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
643 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

    Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF

  • Active comparator
    BIC/FTC/TAF

    Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

    Drug: BIC/FTC/TAF · Drug: Placebo to FDC DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    100 mg DOR/ 0.75 ISL FDC single tablet taken orally once daily

    Also known as: MK-8591A

  • DrugBIC/FTC/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily

  • DrugPlacebo to BIC/FTC/TAF

    Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily

  • DrugPlacebo to FDC DOR/ISL

    Placebo to FDC DOR/ISL in a single tablet taken orally, once daily

    Also known as: Placebo to MK-8591A

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48

    The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the primary outcome measure, the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 48

  2. Percentage of Participants With One or More Adverse Events (AEs) up to Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE up to week 48 is presented.

    Time frame: Up to 48 weeks

  3. Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE up to week 48 is presented.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 96

  2. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 144

  3. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 48

  4. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48, is presented using the FDA snapshot missing data approach.

    Time frame: Week 48

  5. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96, is presented using the FDA snapshot missing data approach.

    Time frame: Week 96

  7. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

    Time frame: Week 144

  8. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144, is presented using the FDA snapshot missing data approach.

    Time frame: Week 144

  9. Mean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 48 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 48 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

    Time frame: Baseline and Week 48

  10. Mean Change From Baseline in CD4+ T-cell Count at Week 96

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 96 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 96 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

    Time frame: Baseline and Week 96

  11. Mean Change From Baseline in CD4+ T-cell Count at Week 144

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 144 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 144 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

    Time frame: Baseline and Week 144

  12. Number of Participants With Viral Drug Resistance-associated Substitutions at Week 48

    Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL having genotypic or phenotypic evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance is presented.

    Time frame: Week 48

  13. Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 96

    Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 96 is presented.

    Time frame: Week 96

  14. Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 144

    Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 144 is presented.

    Time frame: Week 144

  15. Change From Baseline in Body Weight at Week 48

    Body weight was measured and recorded at baseline and week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 48 is presented.

    Time frame: Baseline and Week 48

  16. Change From Baseline in Body Weight at Week 96

    Body weight was measured and recorded at baseline and week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 96 is presented.

    Time frame: Baseline and Week 96

  17. Change From Baseline in Body Weight at Week 144

    Body weight was measured and recorded at baseline and week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 144 is presented.

    Time frame: Baseline and Week 144

  18. Percentage of Participants With One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.

    Time frame: Up to approximately 55 months

  19. Percentage of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.

    Time frame: Up to approximately 40 months

07

Results

Posted Aug 22, 2022

Participant flow

Adult participants living with human immunodeficiency virus-1 (HIV-1) who have been virologically suppressed for ≥3 months and receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) with no history of treatment failure were enrolled.

Base Study (Day 1 to Week 144)
Participant flow — Base Study (Day 1 to Week 144)
MilestoneDOR/ISLBIC/FTC/TAF
Started322321
Treated322319
Completed224211
Not completed98110
Withdrew: Death20
Withdrew: Lost to follow-up58
Withdrew: Physician decision187
Withdrew: Protocol violation01
Withdrew: Sponsor decision1139
Withdrew: Withdrawal by subject5640
Withdrew: Other615
Extension Study (Week 144 to Week 168)
Participant flow — Extension Study (Week 144 to Week 168)
MilestoneDOR/ISLBIC/FTC/TAF
Started132131
Completed102
Not completed122129
Withdrew: Lost to follow-up11
Withdrew: Physician decision21
Withdrew: Sponsor decision91124
Withdrew: Withdrawal by subject282
Withdrew: Other01

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48

The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the primary outcome measure, the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA ≥50 Copies/mL0.60.3
No Virologic Data in Window5.65.3
HIV-1 RNA <50 Copies/mL93.894.4
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Unstratified Miettinen and Nurminen · p = <.001 (p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method.) · Estimated difference: 0.31 · 95% CI -1.19 to 1.96Treatment difference for DOR/ISL group-BIC/FTC/TAF group.
PrimaryPercentage of Participants With One or More Adverse Events (AEs) up to Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE up to week 48 is presented.

Time frame:
Up to 48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With One or More Adverse Events (AEs) up to Week 48
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants With One or More Adverse Events (AEs) up to Week 4871.174.6
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Difference in % (dor/isl- bic/ftc/taf): -3.5 · 95% CI -10.4 to 3.4Based on Miettinen and Nurminen method
PrimaryPercentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE up to week 48 is presented.

Time frame:
Up to 48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 482.52.5
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Difference in % (dor/isl- bic/ftc/taf): -0.02 · 95% CI -2.7 to 2.6Based on Miettinen and Nurminen method
SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA ≥50 Copies/mL0.60.3
No Virologic Data in Window14.38.8
HIV-1 RNA <50 Copies/mL85.190.9
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Unstratified Miettinen and Nurminen · p = <0.001 (p-value for the treatment differences in percent response was calculated using the unstratified Miettinen and Nurminen method. The p-value corresponds to a 1-sided Type 1 error of 0.02497.) · Estimated difference: 0.31 · 95% CI -1.19 to 1.96Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA ≥50 Copies/mL0.91.3
No Virologic Data in Window47.233.2
HIV-1 RNA <50 Copies/mL51.965.5
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -0.32 · 95% CI -2.36 to 1.60Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA <50 Copies/mL93.894.4
No Virologic Data in Window5.65.3
HIV-1 RNA ≥50 Copies/mL0.60.3
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -0.57 · 95% CI -4.38 to 3.21Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48, is presented using the FDA snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 4893.294.0
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -0.88 · 95% CI -4.81 to 3.02Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA <50 copies/mL85.190.9
No Virologic Data in Window14.38.8
HIV-1 RNA ≥50 copies/mL0.60.3
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -5.82 · 95% CI -10.94 to -0.79Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96, is presented using the FDA snapshot missing data approach.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 9684.890.9
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -6.13 · 95% CI -11.28 to -1.08Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
HIV-1 RNA <50 copies/mL51.965.5
No Virologic Data in Window47.233.2
HIV-1 RNA ≥50 copies/mL0.91.3
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -13.65 · 95% CI -21.11 to -6.04Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144, is presented using the FDA snapshot missing data approach.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 14451.965.5
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Estimated difference: -13.65 · 95% CI -21.11 to -6.04Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryMean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 48 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 48 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

Time frame:
Baseline and Week 48
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48
cells/mm^3DOR/ISLBIC/FTC/TAF
Mean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48-19.66 (-39.78 to 0.45)40.51 (20.66 to 60.36)
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Mean difference (dor/isl-bic/ftc/taf): -68.09 · 95% CI -94.75 to -41.43The mean difference is based on an ANCOVA model.
SecondaryMean Change From Baseline in CD4+ T-cell Count at Week 96

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 96 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 96 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

Time frame:
Baseline and Week 96
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in CD4+ T-cell Count at Week 96
cells/mm^3DOR/ISLBIC/FTC/TAF
Mean Change From Baseline in CD4+ T-cell Count at Week 965.36 (-19.71 to 30.42)62.67 (40.44 to 84.90)
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Mean difference (dor/isl-bic/ftc/taf): -65.45 · 95% CI -97.02 to -33.89
SecondaryMean Change From Baseline in CD4+ T-cell Count at Week 144

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 144 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 144 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.

Time frame:
Baseline and Week 144
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in CD4+ T-cell Count at Week 144
cells/mm^3DOR/ISLBIC/FTC/TAF
Mean Change From Baseline in CD4+ T-cell Count at Week 1440.48 (-28.69 to 29.64)66.25 (38.78 to 93.73)
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Mean difference (dor/isl-bic/ftc/taf): -78.13 · 95% CI -114.63 to -41.63
SecondaryNumber of Participants With Viral Drug Resistance-associated Substitutions at Week 48

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL having genotypic or phenotypic evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance is presented.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Viral Drug Resistance-associated Substitutions at Week 48
ParticipantsDOR/ISLBIC/FTC/TAF
Number of Participants With Viral Drug Resistance-associated Substitutions at Week 480—
SecondaryNumber of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 96

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 96 is presented.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 96
ParticipantsDOR/ISLBIC/FTC/TAF
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 960—
SecondaryNumber of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 144

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 144 is presented.

Time frame:
Week 144
Reported as:
Count of participants · Participants
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 144
ParticipantsDOR/ISLBIC/FTC/TAF
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 1440—
SecondaryChange From Baseline in Body Weight at Week 48

Body weight was measured and recorded at baseline and week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 48 is presented.

Time frame:
Baseline and Week 48
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight at Week 48
kilogram (kg)DOR/ISLBIC/FTC/TAF
Change From Baseline in Body Weight at Week 480.23 ± 4.190.55 ± 4.40
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · ANCOVA · p = 0.392 · Treatment difference: -0.30 · 95% CI -0.99 to 0.39Treatment difference for DOR/ISL group-BIC/FTC/TAF group.
SecondaryChange From Baseline in Body Weight at Week 96

Body weight was measured and recorded at baseline and week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 96 is presented.

Time frame:
Baseline and Week 96
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight at Week 96
kilogram (kg)DOR/ISLBIC/FTC/TAF
Change From Baseline in Body Weight at Week 960.29 ± 5.330.72 ± 5.72
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · ANCOVA · p = 0.3263 · Treatment difference: -0.45 · 95% CI -1.34 to 0.45Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryChange From Baseline in Body Weight at Week 144

Body weight was measured and recorded at baseline and week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 144 is presented.

Time frame:
Baseline and Week 144
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight at Week 144
kilogram (kg)DOR/ISLBIC/FTC/TAF
Change From Baseline in Body Weight at Week 1440.63 ± 6.670.84 ± 6.41
Statistical analysis
  • DOR/ISL vs BIC/FTC/TAF · Treatment difference: -0.13 · 95% CI -1.33 to 1.06Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With One or More AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.

Time frame:
Up to approximately 55 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With One or More AEs
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants With One or More AEs96.394.4
SecondaryPercentage of Participants Who Discontinued Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.

Time frame:
Up to approximately 40 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Intervention Due to an AE
Percentage of ParticipantsDOR/ISLBIC/FTC/TAF
Percentage of Participants Who Discontinued Study Intervention Due to an AE22.06.9

Adverse events

Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOR/ISL: Base Study Week 0 - Week 480/322 (0%)14/322 (4.3%)85/322 (26.4%)
DOR/ISL: Base Study Week 48-Week 962/305 (0.7%)19/305 (6.2%)104/305 (34.1%)
DOR/ISL: Base Study Week 96-Week 1440/266 (0%)7/266 (2.6%)151/266 (56.8%)
BIC/FTC/TAF: Base Study Week 0 - Week 480/321 (0%)16/319 (5%)93/319 (29.2%)
BIC/FTC/TAF: Base Study Week 48 - Week 960/301 (0%)11/301 (3.7%)86/301 (28.6%)
BIC/FTC/TAF: Base Study Week 96 - Week 1440/281 (0%)6/281 (2.1%)101/281 (35.9%)
DOR/ISL: Open-Label Extension Week 144-Week 1680/132 (0%)0/132 (0%)34/132 (25.8%)
BIC/FTC/TAF: Open-Label Extension Week 144 - Week 1680/131 (0%)1/131 (0.8%)13/131 (9.9%)
DOR/ISL: Post-Treatment Follow-Up0/196 (0%)3/196 (1.5%)14/196 (7.1%)
BIC/FTC/TAF: Post-Treatment Follow-Up0/152 (0%)0/152 (0%)0/152 (0%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventDOR/ISL: Base Study Week 0 - Week 48DOR/ISL: Base Study Week 48-Week 96DOR/ISL: Base Study Week 96-Week 144BIC/FTC/TAF: Base Study Week 0 - Week 48BIC/FTC/TAF: Base Study Week 48 - Week 96BIC/FTC/TAF: Base Study Week 96 - Week 144DOR/ISL: Open-Label Extension Week 144-Week 168BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168DOR/ISL: Post-Treatment Follow-UpBIC/FTC/TAF: Post-Treatment Follow-Up
VomitingGastrointestinal disorders0/3220/3050/2660/3190/3011/2810/1321/1310/1960/152
Acute myocardial infarctionCardiac disorders2/3221/3051/2660/3190/3010/2810/1320/1310/1960/152
Myocardial infarctionCardiac disorders0/3220/3050/2660/3190/3010/2810/1320/1311/1960/152
OsteoarthritisMusculoskeletal and connective tissue disorders0/3220/3050/2661/3190/3010/2810/1320/1311/1960/152
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3220/3050/2661/3190/3010/2810/1320/1311/1960/152
Atrial fibrillationCardiac disorders0/3221/3051/2660/3190/3010/2810/1320/1310/1960/152
ColitisGastrointestinal disorders0/3221/3051/2660/3190/3011/2810/1320/1310/1960/152
Pyelonephritis acuteInfections and infestations0/3220/3051/2660/3190/3010/2810/1320/1310/1960/152
Tibia fractureInjury, poisoning and procedural complications0/3220/3051/2660/3190/3010/2810/1320/1310/1960/152
MyositisMusculoskeletal and connective tissue disorders0/3220/3051/2660/3190/3010/2810/1320/1310/1960/152
Most frequent other events
Most frequent other events
EventDOR/ISL: Base Study Week 0 - Week 48DOR/ISL: Base Study Week 48-Week 96DOR/ISL: Base Study Week 96-Week 144BIC/FTC/TAF: Base Study Week 0 - Week 48BIC/FTC/TAF: Base Study Week 48 - Week 96BIC/FTC/TAF: Base Study Week 96 - Week 144DOR/ISL: Open-Label Extension Week 144-Week 168BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168DOR/ISL: Post-Treatment Follow-UpBIC/FTC/TAF: Post-Treatment Follow-Up
Lymphocyte count decreasedInvestigations1/32232/30586/2660/3198/30128/28121/1326/1310/1960/152
CD4 lymphocytes decreasedInvestigations1/32228/30563/2660/3194/30128/28115/1326/1310/1960/152
COVID-19Infections and infestations19/32240/30533/26618/31945/30146/2812/1320/1315/1960/152
HeadacheNervous system disorders26/32214/3053/26622/3196/3011/2811/1320/1311/1960/152
DiarrhoeaGastrointestinal disorders8/3227/3057/26620/3197/3012/2812/1320/1312/1960/152
NasopharyngitisInfections and infestations9/32211/30516/2663/31911/30110/2811/1323/1314/1960/152
ArthralgiaMusculoskeletal and connective tissue disorders16/3228/3059/26619/31914/3018/2811/1320/1311/1960/152
Back painMusculoskeletal and connective tissue disorders13/3229/3059/26617/3196/3018/2810/1321/1311/1960/152
HypertensionVascular disorders6/3223/3055/26616/3196/3013/2811/1321/1310/1960/152

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DOR/ISLBIC/FTC/TAFTotal
Mean47.6 ± 12.648.0 ± 11.847.8 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)DOR/ISLBIC/FTC/TAFTotal
Female10578183
Male217243460
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DOR/ISLBIC/FTC/TAFTotal
Hispanic or Latino6455119
Not Hispanic or Latino256261517
Unknown or Not Reported257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DOR/ISLBIC/FTC/TAFTotal
American Indian or Alaska Native325
Asian141327
Native Hawaiian or Other Pacific Islander202
Black or African American5956115
White239240479
More than one race5712
Unknown or Not Reported033
08

Study locations

89 sites
  • Pueblo Family Physicians ( Site 2717)
    Phoenix, Arizona 85015, United States
  • Pacific Oaks Medical Group ( Site 2765)
    Beverly Hills, California 90211, United States
  • Men's Health Foundation ( Site 2749)
    Los Angeles, California 80069, United States
  • Kaiser Permanente Los Angeles Medical Center ( Site 2775)
    Los Angeles, California 90027, United States
  • Eisenhower Medical Center ( Site 2744)
    Palm Springs, California 92264, United States
  • University of California, Davis, Division of ID Research ( Site 2702)
    Sacramento, California 95811, United States
  • Zuckerberg San Francisco General Hospital UCSF ( Site 2743)
    San Francisco, California 94110, United States
  • Whitman-Walker Clinic ( Site 2728)
    Washington D.C., District of Columbia 20009, United States
  • TheraFirst Medical Center ( Site 2742)
    Fort Lauderdale, Florida 33308, United States
  • Midway Immunology and Research ( Site 2759)
    Ft. Pierce, Florida 34982, United States
  • The Kinder Medical Group ( Site 2739)
    Miami, Florida 33133, United States
  • AHF South Beach ( Site 2780)
    Miami Beach, Florida 33140, United States
  • Orlando Immunology Center ( Site 2734)
    Orlando, Florida 32803, United States
  • Triple O Research Institute, P.A. ( Site 2755)
    West Palm Beach, Florida 33407, United States
  • Augusta University ( Site 2752)
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialists Of Atlanta PC ( Site 2719)
    Decatur, Georgia 30033, United States
  • Mercer University ( Site 2738)
    Macon, Georgia 31201, United States
  • Chatham County Health Department ( Site 2731)
    Savannah, Georgia 31401, United States
  • Hennepin County Medical Center ( Site 2733)
    Minneapolis, Minnesota 55415, United States
  • Kansas City CARE Clinic ( Site 2718)
    Kansas City, Missouri 64111, United States
  • ID Care ( Site 2751)
    Hillsborough, New Jersey 08844, United States
  • Icahn School of Medicine at Mount Sinai ( Site 2700)
    New York, New York 10029, United States
  • Montefiore Einstein Center ( Site 2730)
    The Bronx, New York 10467, United States
  • North Texas ID Consultants, PA ( Site 2707)
    Dallas, Texas 75246, United States
  • The Crofoot Research Center, Inc. ( Site 2715)
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research ( Site 2769)
    Longview, Texas 75605, United States
  • Dr. Peter Shalit, MD ( Site 2770)
    Seattle, Washington 98104, United States
  • Multicare Health System ( Site 2713)
    Spokane, Washington 99204, United States
  • St Vincent's Hospital ( Site 3807)
    Darlinghurst, New South Wales 2010, Australia
  • Taylor Square Private Clinic ( Site 3804)
    Darlinghurst, New South Wales 2010, Australia
  • Holdsworth House Medical Practice ( Site 3800)
    Sydney, New South Wales 2010, Australia
  • Holdsworth House Medical Practice - Brisbane ( Site 3810)
    Brisbane, Queensland 4006, Australia
  • Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 3812)
    Herston, Queensland 4029, Australia
  • The Alfred Hospital ( Site 3802)
    Melbourne, Victoria 3004, Australia
  • Prahran Market Clinic (PMC) ( Site 3806)
    Melbourne, Victoria 3181, Australia
  • Medical University Vienna ( Site 3402)
    Vienna, State of Vienna 1090, Austria
  • Sozialmedizinisches Zentrum Sued - Kaiser-Franz-Josef-Spital ( Site 3400)
    Vienna, State of Vienna 1100, Austria
  • Social Medical Center - Otto Wagner Hospital ( Site 3404)
    Vienna, State of Vienna 1145, Austria
  • LKH Graz West ( Site 3401)
    Graz, Styria 8020, Austria
  • Vancouver ID Research and Care Centre Society ( Site 2800)
    Vancouver, British Columbia V6Z 2C7, Canada
  • Hamilton Health Sciences ( Site 2803)
    Hamilton, Ontario L8L 2X2, Canada
  • Clinique de Medecine Urbaine du Quartier Latin ( Site 2804)
    Montreal, Quebec H2L 4E9, Canada
  • Clinique Medicale L Actuel ( Site 2814)
    Montreal, Quebec H2L 4P9, Canada
  • Helsinki University Hospital ( Site 3200)
    Helsinki, Uusimaa 00029, Finland
  • Hopital Edouard Herriot ( Site 3126)
    Lyon, Ain 69003, France
  • CHU de Nice Hopital Archet 1 ( Site 3103)
    Nice, Alpes-Maritimes 06202, France
  • Hopital Europeen Marseille ( Site 3117)
    Marseille, Bouches-du-Rhone 13003, France
  • Hopital Foch ( Site 3129)
    Suresnes, Hauts-de-Seine 92151, France
  • CHU de Montpellier - Hopital Saint-Eloi ( Site 3121)
    Montpellier, Herault 34295, France
  • CHU Hotel Dieu Nantes ( Site 3120)
    Nantes, Loire-Atlantique 44093, France
  • Centre Hospitalier Regional du Orleans ( Site 3108)
    Orléans, Loiret 45000, France
  • CHU de Nancy Hopital Brabois Adultes ( Site 3128)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
  • Centre Hospitalier de Tourcoing ( Site 3100)
    Tourcoing, Nord 59208, France
  • Hopital Saint-Antoine ( Site 3113)
    Paris, 75012, France
  • Hopital Pitie Salpetriere ( Site 3111)
    Paris, 75013, France
  • Hopital Tenon ( Site 3118)
    Paris, 75020, France
  • MVZ Karlsplatz Dr.med.Hans Jaeger ( Site 3002)
    Munich, Bavaria 80335, Germany
  • Klinikum der LMU München ( Site 3004)
    Munich, Bavaria 80336, Germany
  • Klinikum rechts der Isar der Technischen Universitat ( Site 3005)
    Munich, Bavaria 81675, Germany
  • Infektiologikum ( Site 3001)
    Frankfurt am Main, Hesse 60596, Germany
  • Medizinische Hochschule Hannover ( Site 3012)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Bonn ( Site 3000)
    Bonn, North Rhine-Westphalia 53127, Germany
  • Universitaetsklinikum Essen ( Site 3007)
    Essen, North Rhine-Westphalia 45122, Germany
  • ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 3003)
    Berlin, 10439, Germany
  • EPIMED GmbH ( Site 3008)
    Berlin, 12167, Germany
  • ICH Study Center GmbH & Co.KG ( Site 3009)
    Hamburg, 20146, Germany
  • Universitaetsklinikum Hamburg- Eppendorf (UKE) ( Site 3010)
    Hamburg, 20246, Germany
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 3501)
    Milan, Lombardy 20122, Italy
  • Universita' Vita Salute. Ospedale San Raffaele ( Site 3502)
    Milan, 20127, Italy
  • Azienda Ospedaliera San Paolo ( Site 3503)
    Milan, 20142, Italy
  • ASST Fatebenefratelli-Ospedale Sacco ( Site 3500)
    Milan, 20157, Italy
  • A.O.R.N. dei Colli - Ospedale Cotugno ( Site 3507)
    Naples, 80131, Italy
  • National Hospital Organization Nagoya Medical Center ( Site 7203)
    Nagoya, Aichi-ken 460-0001, Japan
  • National Hospital Organization Osaka National Hospital ( Site 7202)
    Osaka, 540-0006, Japan
  • Center Hospital of the National Center for Global Health and Medicine ( Site 7201)
    Tokyo, 162-8655, Japan
  • CAIMED Center - Ponce School of Medicine ( Site 2903)
    Ponce, 00716, Puerto Rico
  • Puerto Rico CONCRA ( Site 2904)
    Rio Piedras, 00925, Puerto Rico
  • Clinical Research Puerto Rico Inc ( Site 2900)
    San Juan, 00909, Puerto Rico
  • Hope Clinical Research, Inc. ( Site 2902)
    San Juan, 00909, Puerto Rico
  • Hospital Universitari Germans Trias i Pujol ( Site 3601)
    Badalona, Barcelona [Barcelona] 08916, Spain
  • Hospital Universitari Vall d Hebron ( Site 3602)
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Hospital Universitari de Bellvitge ( Site 3612)
    LHospitalet de Llobregat, Barcelona [Barcelona] 08907, Spain
  • Hospital Clinic i Provincial ( Site 3600)
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Maranon ( Site 3603)
    Madrid, 28007, Spain
  • Hospital Universitario Infanta Leonor ( Site 3606)
    Madrid, 28031, Spain
  • Hospital Universitario Ramon y Cajal ( Site 3611)
    Madrid, 28034, Spain
  • Hospital 12 de Octubre de Madrid ( Site 3605)
    Madrid, 28041, Spain
  • Hospital Universitario La Paz ( Site 3604)
    Madrid, 28046, Spain
  • Hospital Universitario Virgen de la Victoria ( Site 3609)
    Málaga, 29010, Spain
09

References and documents

Publications

  • Mills AM, Rizzardini G, Ramgopal MN, Osiyemi OO, Bogner JR, Hagins DP, Paredes R, Reynes J, Rockstroh JK, Carr A, Su FH, Klopfer SO, Eves K, Plank RM, Correll T, Fox MC. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2024 Jun;11(6):e357-e368. doi: 10.1016/S2352-3018(24)00030-4. Epub 2024 May 8. PubMed 38734016 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Aug 2021, 18 months.

Results were first posted in Aug 2022, 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 18 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2020
First posted
Jan 10, 2020
StartActual
Feb 18, 2020
Primary completionActual
Aug 26, 2021
CompletionActual
Feb 27, 2025
Results first posted
Aug 22, 2022
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04223791
Responsible party
Sponsor
First posted
Jan 10, 2020
Start date
Feb 18, 2020
Primary completion
Aug 26, 2021
Completion
Feb 27, 2025
Results posted
Aug 22, 2022
Last update
Mar 27, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion